Tiziana Life Sciences PLC   | AIM:TILS


To access a complete list of market notifications made by the Company in the past twelve months please click here »

For a complete list of our corporate documents please see our Investor Relations section »

Mar 24, 2017

Exercise of Warrants & Issue of Equity

Exercise of warrants over 1,789,524 ordinary shares in the Company at 32p per share, provides the Company with gross proceeds of £572,648.

Read more »

Mar 14, 2017

Tiziana Life Sciences Appoints Dr. Arun Sanyal to its Scientific Advisory Board

Dr. Arun Sanyal is a distinguished professor and a key opinion leader in liver diseases such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

Read more »

Jan 16, 2017

Warrant Expiry – Reminder

Update in respect of the series “B” warrants issued to investors on 18 June 2014 (“Warrants”), in connection with a fundraising by the Company.

Read more »

Jan 3, 2017

Tiziana Life Sciences in-licenses NI-1201, a fully human anti-IL- 6R monoclonal antibody

Exclusive world-wide license expands therapeutic pipeline in key immunological areas.

Read more »

Nov 16, 2016

Tiziana Life Sciences Announces New Data with Foralumab, a Fully Human Anti-CD3 Antibody Being Developed as an Oral Therapy for NASH and Autoimmune Diseases

New data from animal studies demonstrates potential of foralumab (NI-0401) for  NASH, diabetes and other inflammatory diseases.

Read more »

Nov 7, 2016

Grant of options

Tiziano Lazzaretti, the Company's Chief Financial Officer, has been awarded options over 100,000 ordinary shares in the capital of the Company.

Read more »

Sep 29, 2016

Interim Results for the Six Months Ended 30 June 2016

Advancing pipeline of next generation therapeutics and diagnostics for oncology and immune diseases of high unmet need

Read more »

Download Half-year Report (PDF) »

Sep 15, 2016

Confirmation of Capital Reduction

Confirms capital reduction approved by shareholders pursuant to Resolution 9 passed at the Annual General Meeting (“AGM”).

Read more »

Aug 18, 2016

Change of Registered Address

Our registered office address has changed to: 3rd Floor, 11-12 St. James's Square, London, United Kingdom, SW1Y 4LB.

Read more »

Jul 18, 2016

Tiziana acquires a unique bio-repository from Shardna SpA and establishes LonGevia Genomics Srl, a Sardinian based subsidiary to further enhance and develop its portfolio

Purchases key assets from Shardna SpA.

Read more »

Jun 30, 2016

Result of Annual General Meeting ("AGM") and Issue of Equity

Announces that at the AGM held today, all resolutions proposed at the meeting were duly passed.

Read more »

Jun 29, 2016

Exercise of Warrants, Conversion of Convertible Loan Notes and Issue of Equity

Announces exercise warrants and loan note conversion notifications.

Read more »

Access our FULL NEWS ARCHIVE on the London Stock Exchange website »


Tiziana News & Events

Updated with our latest news, announcements, featured news articles, and forthcoming events. See our investor relations pages and media resources areas for other information.


May 7, 2015

Cardiff University - New Anti-Cancer Stem Cell Technology

Tiziana exclusively licenses novel anti-cancer stem cell agent, targeting aggressive tumour forming cells

Read more »

Dec 22, 2014

Novimmune SA - Foralumab

Fully human anti-CD3 mAb has shown encouraging results in phase I/II trials in GVHD and Crohn’s Disease - Tiziana will evaluate the drug’s potential in a number of inflammatory diseases.

Read more »


FTI Consulting

Simon Conway / Rob Winder

Tel.:  +44 (0)20 3727 1000


E-mail:  info@tizianalifesciences.com